Media

Recent News

Ottawa, ON /GlobeNewswire/ March 6th, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) reported today its unaudited financial results for Q1 2019. For the three-month period ended January 31, 2019, the Corporation reported revenues of $322,125 – a doubling of revenues compared to revenues of $143,201 for the three-month period ended January 31, …Read More

Ottawa, ON /GlobeNewswire/ February 28, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”), is pleased to announce that its partner in the Philippines, UNAHCO, has purchased 2 metric tons of OxC-beta™ Livestock, and follows an order of 2 metric tons delivered to UNAHCO in November 2018. UNAHCO forecasts demand to grow in 2019 as it expands …Read More

Ottawa, ON /GlobeNewswire/ February 20, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has signed a partnership with CSA Animal Nutrition providing for the sales and distribution ofOxC-beta™Livestock (“OxC-beta”)by CSA in the United States. Under the terms of the agreement, CSA will coordinate commercial scale validation research with potential customers …Read More

Ottawa, ON /GlobeNewswire/ January 31, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”) reported its audited financial results for the year ended October 31, 2018. Unless otherwise noted, all figures are in Canadian currency. The Corporation’s audited year end Financial Statements and its Management’s Discussion and Analysis for the year ended October 31, 2018 have been …Read More

Ottawa, ON /GlobeNewswire/ January 18, 2019 – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support …Read More

I think if people keep their eyes on the size of the prize, [they’ll see] the livestock market is in the billions of dollars; our share of that would be in the hundreds of millions if we roll out successfully. The human market is untouched. The companion animal market is also big. We’ve spent years proving it works; everyone agrees it works. Now is the time to roll it out commercially.

CTV NEWS, TORONTO – A hundred years ago, a small wound could result in death if an infection spread. That could become reality again as the world threatens to return to a pre-antibiotic era due to antibiotic resistance.

Some have pointed to the widespread use of antibiotics in livestock feed as a culprit, resulting in urgent calls to quell their use and find alternatives.